Marker Therapeutics (MRKR) Stock: Buy, Sell, or Hold?
MRKR - Marker Therapeutics, Inc. Common Stock
$1.05
-0.02 (-1.87%)
▼
5d:
-11.76%
30d:
-19.23%
90d:
-28.57%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When MRKR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MRKR is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MRKR is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MRKR is currently trading at $1.05, which is considered oversold relative to its 30-day fair value range of $1.11 to $1.36.
Technical Outlook: Technically, MRKR is in a downtrend. Immediate support is located at $0.98, while resistance sits at $1.31.
Market Sentiment: MRKR scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.87 (+649.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRKR is in a downtrend. Immediate support is located at $0.98, while resistance sits at $1.31.
Market Sentiment: MRKR scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.87 (+649.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.11 -
$1.36
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 649.2% below Wall St target ($7.87)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.11 -
$1.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.98
Resistance Level
$1.31
Current Trend
Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.98
Wall Street Target
$7.87
(+649.2%)
Revenue Growth (YoY)
-51.0%
Profit Margin
-245.5%
Share & Embed Analysis
Last updated: October 02, 2026 2:36 AM ET
Data refreshes hourly during market hours. Next update: 3:36 AM
Data refreshes hourly during market hours. Next update: 3:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRKR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
MRKR is a key holding in these high-performance investment strategies.
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 68 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 63 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 60 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 68 BUY |
